Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...

Telehealth firms Teladoc and LifeMD said on Thursday they had signed an agreement to offer Eli Lilly's weight-loss drug ...

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Zeroing in on Eli Lilly, the company is already well established with Zepbound, which should continue to sell briskly as the world waits for a more powerful and efficacious obesity drug to hit the ...

Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.